TY - JOUR AU - Chhetri, Dibyashree AU - Gnanasampanthapandian, Dhanavathy AU - Palaniyandi, Kanagaraj PY - 2023/03/10 Y2 - 2024/03/29 TI - Epigenetic Regulation of Tamoxifen-Resistant Breast Cancer: An Update JF - Journal of Endocrinology and Reproduction JA - JER VL - 26 IS - 4 SE - Review Article DO - 10.18311/jer/2022/31013 UR - https://informaticsjournals.com/index.php/jer/article/view/31013 SP - 221-237 AB - <p>Breast cancer is the most common cause of death in women around the world. Epigenetic changes modulate transcriptional activity in several diseases, including cancer. Cancer epigenetics explains gene expression changes without DNA mutations. Aberrant DNA methylation, histone modifications, and mRNA expression promote tumоr growth and metastasis. In cancer cells, chemo-resistance occurs via Multidrug Resistance (MDR), apoptotic suppression, DNA damage response, epigenetic alterations, and competitive endogenous RNA. Owing to drug resistance, quiescence, and varied cancer cell production, Cancer Stem Cells (CSCs) are critical to tumоr formation, metastasis, and recurrence after therapy. In addition, MDR promotes drug efflux, enhanced secretion of growth factors, and DNA modifications in cancer patients, thereby causing fatalities in cancer patients. Heterogeneity and epigenetic plasticity cause drug resistance due to various factors. However, the molecular mechanism of epigenetic drug resistance is still unravelled completely. Overexpressed c-MYC leads to cancer and tamoxifen resistance. Despite the molecular underpinning of cancer development, drug resistance is continued in a myriad number of cases. Epigenetic changes affect CSCs viability and tumоr aggressiveness. These processes can be blocked by medicines. Tamoxifen is used widely for breast cancer treatment; however, latent treatments have emerged as a tamoxifen-resistant phenotype. Epigenetic modifications cause resistance by upregulating and altering the tumоr microenvironment and deregulating the immune response. The knowledge of epigenetic pathways in clinical treatment resistance may enhance the outcome of cancer patients. Multifactorial heterogeneous resistance is common in many targeted therapies. Many resistance mechanisms to targeted therapy may converge, including route reactivation. This review summarizes the epigenetic alterations, MDR, and development of tamoxifen resistance in breast cancer.</p> ER -